Gas chromatographic determination of oxprenolol in human plasma

Sioufi, A.; Colussi, D.; Mangoni, Patrick

doi:10.1016/s0378-4347(00)84772-6

Cited by 21 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The oxprenolol assay was done after extraction and derivatization by a gaschromatographic method with electron-capture detector (Sioufi et al 1983). A GC Fractovap 2450 (Carlo Erba, Milan) was used; glass column (length 0.95 m; i.d.…”

Section: Oxprenolol Assay In Plasma Samplesmentioning

confidence: 99%

Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro / in vivo characterization

Preda

Leucuţa

2003

Journal of Microencapsulation

View full text Add to dashboard Cite

Biologically adhesive delivery systems offer important advantages over conventional drug-delivery systems. In this paper, microspheres intended as a sustained release carrier for oral or nasal administration have been prepared by associating a known bioadhesive polymer, poly(acrylic acid), in gelatin microspheres. A model drug oxprenolol hydrochloride was chosen. It was found that some of the formulation variables can influence the characteristics of the beads in a controlled manner. The internal structure of the microspheres studied by X-ray diffraction, thermal analysis and optical microscopy showed the absence of drug crystals in microspheres and a lowering in the glass transition temperature. The dynamic swelling of the beads obeyed the square root of time and a shift from the diffusional to the relaxational process dependent on the content of poly(acrylic acid) in gelatin microspheres was observed. As expected, drug release from gelatin/poly(acrylic acid) microspheres was influenced by the poly(acrylic acid) content in beads, by the particle size of microspheres and by the pH of the medium. The mechanism of release was analysed by applying the empirical exponential equation and by calculation of the approximate contribution of the diffusional and relaxational mechanisms to the anomalous release process by fitting the data to the coupled Fickian/Case II equation. In vitro and in vivo experiments in rats showed good adhesive characteristics of the gelatin/poly(acrylic acid) microspheres, which were greater if the poly(acrylic acid) content was greater. A significant retardation in gastric and intestinal emptying time of the beads was observed. This was also suggested by the bioavailability of the model drug after intragastric and intranasal administration of the microspheres. The pharmacokinetic parameters after microsphere administration were more appropriate to a slow release drug-delivery system. The work suggests the potential of this pharmaceutical delivery system as an alternative controlled-release dosage form, either for oral or nasal administration.

show abstract

Section: Oxprenolol Assay In Plasma Samplesmentioning

confidence: 99%

Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro / in vivo characterization

Preda

Leucuţa

2003

Journal of Microencapsulation

View full text Add to dashboard Cite

show abstract

“…Recovery of oxprenolol from spiked blank plasma is complete and the coefficient of variation for reproducibility is about 5% over the whole range 10-1500 ng mI74. Further details of this method in a slightly modified form have been published by Sioufi et al (1983).…”

Section: Drug and Metabolite Assaymentioning

confidence: 99%

Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.

Bradbrook¹,

Babiker²,

Crome³

et al. 1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

Oxprenolol in an Oros 8/130 sustained release osmotic pump system (equivalent to 120 mg oxprenolol hydrochloride in a conventional formulation and releasing 8 mg h‐1) was given to eight normal young subjects (mean age 23 years) and eight elderly hypertensive patients (mean age 77 years). The plasma concentration‐time profiles of oxprenolol were determined over 32 h using gas liquid chromatography after the initial dose and following seven doses. The elderly patients had a significantly higher AUC and maximum plasma oxprenolol concentration following both the first and final doses studied. It is unlikely that this difference is due to a prolonged absorption phase in the elderly patients. Reduced drug clearance seems the most probable explanation.

show abstract

“…Oxprenolol concentrations in plasma, amniotic fluid and milk were determined by gas chromatography according to a method described for assays in plasma (Sioufi et al, 1983). Its limit of quantitation is 33 nmol/l (CV, < 10%).…”

Section: Analytical Proceduresmentioning

confidence: 99%

Oxprenolol placental transfer, plasma concentrations in newborns and passage into breast milk.

Sioufi¹,

Hillion²,

Lumbroso³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

Thirty-two pregnant hypertensive patients were treated with oxprenolol administered in combination with dihydralazine as Trasipressolg tablets. Before delivery, oxprenolol was demonstrable in the maternal plasma and the amniotic fluid. The free fraction of oxprenolol in the maternal serum (15% + 7.8; mean + s.d.; n = 25) was similar to that in normal serum. At the end of delivery, oxprenolol was found in both the maternal and umbilical plasma in most cases. Measurable, but low oxprenolol concentrations were present in the newborn plasma. After delivery, oxprenolol was demonstrable in the maternal plasma and breast milk. An infant weighing 3 kg and consuming 500 ml of breast milk per day would receive a maximum dose 60 times less than the normal daily dose for a hypertensive adult (4 mg/kg).

show abstract

Gas chromatographic determination of oxprenolol in human plasma

Cited by 21 publications

References 10 publications

Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro / in vivo characterization

Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro / in vivo characterization

Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.

Oxprenolol placental transfer, plasma concentrations in newborns and passage into breast milk.

Contact Info

Product

Resources

About